A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG
Launched by UNIVERSITY OF CALIFORNIA, DAVIS · Dec 15, 2021
Trial Information
Current as of July 08, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • 18F-PSMA (n=3) and 68Ga-PSMA (n=3)
- Inclusion criteria:
- • Persons \>18 yo with suspected prostate cancer metastasis
- • Prior imaging study (CT, and/or MRI and/or Bone scan and/or Fluciclovine scan) suspicious for metastatic disease, obtained within 4 months from the research scan date.
- • 68Ga DOTATATE (n=3) or 64Cu-DOTATATE (n=3)
- Inclusion Criteria:
- • Persons \> 18 yo suspicious for or diagnosed with somatostatin receptor positive neuroendocrine tumors (NETs)
- • Prior DOTATATE PET/CT scan suspicious for tumor obtained not earlier than 4 months from the research scan date.
- Exclusion Criteria:
- • • Recent administration of long-acting somatostatin analogs
- Exclusion Criteria for all participants:
- • Adults unable to consent
- • Pregnant/lactating persons
- • Prisoners
- • Unable to lie supine for up to 90 minutes at different timepoints in the PET scanner
- • Uncontrolled claustrophobia
- • Any significant medical condition that in the opinion of the investigator would prevent the participant from participating and/or adhering to study related procedures or interfere with participant safety
About University Of California, Davis
The University of California, Davis (UC Davis) is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials and studies. With a strong focus on interdisciplinary collaboration, UC Davis leverages its extensive expertise in medical research, education, and patient care to drive breakthroughs in various fields, including medicine, public health, and agriculture. The university's clinical trial programs emphasize rigorous scientific methodology and ethical standards, aiming to translate research findings into impactful treatments and improved patient outcomes. Through its state-of-the-art facilities and a dedicated team of researchers and healthcare professionals, UC Davis is at the forefront of transforming healthcare practices and addressing critical health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sacramento, California, United States
Patients applied
Trial Officials
Lorenzo Nardo, MD
Principal Investigator
University of California, Davis
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials